finance
-
The Hidden Variable Inside MedTech Scale-Ups Right Now
In the previous article, I wrote about the moment optionality begins to narrow in MedTech scale-ups. The natural question for boards is what determines whether that shift is recognised early, or only noticed once timelines begin to stretch. Across portfolios, the answer is rarely capital, rarely technology, and it is almost never effort. The hidden…
-
When Regulatory Conversations Quietly Rewrite the Strategy
Most MedTech strategies are not rewritten in board meetings. They are rewritten gradually, often almost invisibly, through conversations with regulators that at the time appear to be clarifications rather than decisions. This is not because regulators intend to shape company direction. It happens because evidence-based environments reveal reality step-by-step, and each clarification alters what the…

